C17orf45 Inhibitors
Compounds like Staurosporine, LY294002, and Rapamycin act on kinases and kinases-related pathways such as PI3K/AKT and mTOR, which are central to cell growth and survival, and could thus indirectly affect C17orf45 activity if it is a part of or regulated by these pathways. SB203580 and PD98059 are inhibitors of the MAPK signaling pathway, which is involved in cell proliferation, differentiation, and stress responses, and could have an impact on C17orf45 if it is regulated by this pathway.
MG132 and Bortezomib are proteasome inhibitors that prevent the degradation of proteins, which may stabilize C17orf45 if it is normally marked for degradation. Thapsigargin and 2-Deoxy-D-glucose disrupt calcium homeostasis and glycolysis, respectively, and could influence C17orf45 activity if it is associated with calcium signaling or cellular metabolism. U0126, like PD98059, targets the MEK/ERK pathway and could have implications for C17orf45 regulation. ZM-447439 inhibits Aurora kinases, which could affect C17orf45 if it has a role in cell cycle control.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum kinase inhibitor that can affect numerous signaling pathways potentially regulated by C17orf45. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can disrupt PI3K/AKT signaling, potentially affecting the activity of C17orf45 if it is part of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can downregulate mTOR signaling, indirectly influencing the activity of C17orf45 if it is linked to this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can impede p38 MAPK signaling, potentially modulating C17orf45 activity if it is involved in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that can block the MAPK/ERK pathway, potentially affecting C17orf45 if it is associated with this pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can lead to an accumulation of cellular proteins, potentially affecting C17orf45 turnover if it is degraded by the proteasome. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressant that can inhibit calcineurin, potentially affecting C17orf45 if calcineurin signaling regulates its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A SERCA pump inhibitor that disrupts calcium homeostasis, potentially affecting C17orf45 if calcium signaling is important for its function. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glycolysis inhibitor that can alter energy metabolism, potentially affecting C17orf45 if it is involved in metabolic regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can affect protein degradation, potentially influencing C17orf45 stability if it is a proteasome substrate. | ||||||